Epidemiological trends of rotavirus diarrhoea in infant and young children before and after introduction of rotavirus vaccine in rural Gambia

M. Jahangir Hossain1*, Dilruba Nasrin2, Anna Roose2, Joquina Chiquita M. Jones1, Henry Badji3, Sharon M. Tennant2, Irene Kasumba2, Milagritos Tapia2, Helen Powell2, Kathleen M. Neuzil2, Martin Antonio1, Syed M.A. Zaman1, Karen L. Kotloff2

1Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia
2Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

Rotavirus (RV) is the leading etiology of moderate-to-severe diarrhoea (MSD) during the first two years of life. We present epidemiological trends of RV infection in children age <5 years old before and after introduction of RV vaccine (RVV) in rural Gambia using data from the Vaccine Impact on Diarrhoea in Africa (VIDA) study and the Global Enteric Multi-Centre Study (GEMS). GEMS (2008-2010) and VIDA (2015-2018) were 36-month, age-stratified matched case-control studies designed to assess the incidence, etiology and clinical consequences MSD among children aged <5 years. RVV was introduced in The Gambia in August 2013, before VIDA study.

MSD cases (children with diarrhoea [≥3 loose stools/24h], with at least one of the following: dysentery, sunken eyes, decreased skin turgor, IV rehydration, and hospitalization) were enrolled from sentinel health centres in 3 age-strata (0-11, 12-23 and 24-59 months). Diarrhoea-free, healthy controls matched for age, sex, time and community were enrolled from the community. Only MSD cases were included in the analysis of trend of RV infection. Enrolled cases provided a stool sample at the time of enrolment, which was tested for RV by enzyme-linked immunosorbent assay (EIA).

During the VIDA study, 1678 MSD cases were enrolled over 3 years. Among MSD cases, RV prevalence was lower in VIDA (11.0%) compared to GEMS (19.9%). The median age (interquartile range) of RV cases was higher in VIDA compared to GEMS (13 m, range: 8-21 m v. 12 m, range: 8-18 m). Most of the RV in MSD cases was isolated between December to June both in VIDA and GEMS (184/185, 99.5% v. 203/205, 99.0%) and peaked between January to April (174/185, 94.1% v. 170/205, 82.9%). The prevalence of RV decreased in all age-strata in VIDA compared to GEMS (14.8% v. 25.0% in 0—11 m, 11.3% v. 17.6% in 12-23 m, and 6.7% vs 14.4% in 24-59 m).

After RVV introduction, RV prevalence in Gambian children with MSD has decreased. However, RV remains a major cause of MSD in The Gambia.